Comparative infection risk in CAR T vs bispecific antibodies in B-cell lymphoma: a systematic review and meta-analysis.

This meta-analysiscompares rates of infections between commercially approved CAR T and BsAb therapy in patients with B-cell non-Hodgkin lymphoma (B-NHL).

这项荟萃分析比较了在B细胞非霍奇金淋巴瘤（B-NHL）患者中，商业批准的CAR T和BsAb疗法的感染率。

We conducted a systematic reviewfor prospective trials assessing commercially approved CAR T and BsAbs in patients with B-NHL.

我们对评估B-NHL患者中商业批准的CAR T和BsAbs的前瞻性试验进行了系统评价。

Twenty-five studies comprising 3202 patients were included in the analysis.

分析中包括了25项研究，共涉及3202名患者。

We used random effects models to evaluate all-grade infections, grade 3+ infections, and infection-related mortality, calculating both pooled rates per patient and per patient-month.

我们使用随机效应模型评估了所有级别的感染、3级及以上感染以及与感染相关的死亡率，计算了每位患者和每位患者月的汇总率。

While CAR T and BsAbs had similar rates of all-grade infections per patient (0.44 vs 0.54; P = .18), BsAbs had a higher rate of infection per patient-month (0.0397 vs 0.0167; P = .0012).

尽管CAR T和BsAbs在每位患者的所有级别感染率上相似（0.44对比0.54；P = .18），但BsAbs在每位患者月的感染率上更高（0.0397对比0.0167；P = .0012）。

Similarly, CAR T and BsAbs had similar rates of grade 3+ infections per patient (0.16 vs 0.22; P = .08), while BsAbs had a higher rate of grade 3+ infections per patient-month (0.0165 vs 0.0069; P = .0003).

同样地，CAR T和BsAbs在每位患者中出现3级或以上感染的比率相似（0.16比0.22；P = .08），然而BsAbs在每位患者-月出现3级或以上感染的比率更高（0.0165比0.0069；P = .0003）。

CAR T and BsAb products had similar rates of infection-related mortality per patient (0.04 vs 0.03; P = .26) and per patient-month (0.0023 vs 0.0022; P = .96).

CAR T和BsAb产品在每位患者中与感染相关的死亡率相似（0.04比0.03；P = .26），以及在每位患者-月中的死亡率也相似（0.0023比0.0022；P = .96）。

Our findings point to the potential increased burden of infections over time in patients receiving BsAb therapy, particularly for patients on indefinite therapy.

我们的研究结果表明，接受双特异性抗体治疗的患者随时间推移感染负担可能增加，尤其是对于那些接受长期治疗的患者。